http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-20012973-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73f9f9fbe28821dcb208bfd266b5ddfa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D223-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D223-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-04 |
| filingDate | 2000-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd55f6598152e3cd5ee87ee61777b2b9 |
| publicationDate | 2002-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CZ-20012973-A3 |
| titleOfInvention | Dopamine D1 receptor agonists |
| abstract | The invention provides 2,3,4,5-tetrahydro-1H-3-benzazepines of general formula (I) wherein: R<1> is hydrogen, halogen, C1-C4 alkyl, or CF3; R<2> is hydrogen, methyl, or lower alkenyl of 3-5 carbon atoms; R<3> and R<4> together form a furan, dihydrofuran, thiophene, dihydrothiophene, cyclopentane or cyclohexane ring and R<5> is hydrogen or R<4> and R<5> together form a furan, dihydrofuran, thiophene, dihydrothiophene, cyclopentane or cyclohexane ring and R<3> is hydrogen; R<6> is hydrogen, halogen, CF3, CN, NO2 or NH2; R<7> is hydrogen, halogen, CF3, CN, NO2 or NH2. The specific combination of substituents: R1 = H, R2 = H and R4 and R5 together forming a cyclohexane ring is excluded, namely 1-(5,6,7,8-tetrahydronaphthalen-2-yl)-2,3,4,5-tetrahydro-1H-benzol[d]azepine-7,8-diol. The compounds of the invention provide therapeutic agents that selectively interact positively with postsynaptic dopamine D1 receptors in the striatum, directly or in-directly (termed dopamine D1 agonists) and are particularly valuable as anti-Parkinsonian agents. |
| priorityDate | 1999-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.